| Original language | English |
|---|---|
| Journal | Kidney International Reports |
| Early online date | 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 2023 |
Keywords
- diabetic kidney disease
- glomerular filtration rate
- insulin infusion
- kidney hemodynamics
- kidney perfusion
- renal vascular resistance
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function. / van Baar, Michaël J. B.; van Bommel, Erik J. M.; Touw, Daan J. et al.
In: Kidney International Reports, 2023.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function
AU - van Baar, Michaël J. B.
AU - van Bommel, Erik J. M.
AU - Touw, Daan J.
AU - Nieuwdorp, Max
AU - Joles, Jaap A.
AU - Krebber, Merle M.
AU - Bjornstad, Petter
AU - van Raalte, Daniël H.
N1 - Funding Information: This trial was funded by AstraZeneca as an investigator-initiated study. The funder had no role in the study design, the analyses or interpretation of the data, or drafting the manuscript. The funder had no role in the decision to submit this manuscript for publication. Funding Information: PB reports serving as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. PB also serves on the advisory boards and/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX. DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk. All honoraria are paid to his employer (Amsterdam UMC, location VUMC). DJT has received research grants from Chiesi Pharmaceutici and acts as consultant for PureIMS and Sanquin. All grants and honoraria are paid to the UMCG. All the other authors declared no competing interests. Funding Information: PB receives salary and research support from National Institute of Diabetes and Digestive and Kidney Diseases ( R01 DK129211 , R01 DK132399 , R21 DK129720 , K23 DK116720 , UC2 DK114886 ), National Heart, Lung, and Blood Institute ( R01 HL165433 ), JDRF (3-SRA-2022-1097-M-B, 3-SRA-2022-1243-M-B, 3-SRA-2022-1230-M-B), Boettcher Foundation , American Heart Association ( 20IPA35260142 ), Ludeman Family Center for Women’s Health Research at the University of Colorado, the Department of Pediatrics, Section of Endocrinology, and Barbara Davis Center for Diabetes at University of Colorado School of Medicine. MN is supported by a ZONMW VICI grant 2020 (09150182010020).
PY - 2023
Y1 - 2023
KW - diabetic kidney disease
KW - glomerular filtration rate
KW - insulin infusion
KW - kidney hemodynamics
KW - kidney perfusion
KW - renal vascular resistance
UR - http://www.scopus.com/inward/record.url?scp=85148747272&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ekir.2023.01.001
DO - https://doi.org/10.1016/j.ekir.2023.01.001
M3 - Article
JO - Kidney International Reports
JF - Kidney International Reports
SN - 2468-0249
ER -